KRBP
NASDAQKiromic BioPharma Inc.
Latest news
25 items- SECKiromic BioPharma Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year8-K - Kiromic Biopharma, Inc. (0001792581) (Filer)
- SECKiromic BioPharma Inc. filed SEC Form 8-K: Other Events8-K - Kiromic Biopharma, Inc. (0001792581) (Filer)
- SECAmendment: SEC Form S-1/A filed by Kiromic BioPharma Inc.S-1/A - Kiromic Biopharma, Inc. (0001792581) (Filer)
- PRKiromic BioPharma Reports Patient 4 in Deltacel-01 Clinical Trial Reaches 10-Month Progression-Free SurvivalKiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") reports continued favorable efficacy results from the 10-month follow-up visit for the fourth patient enrolled in its Deltacel-01 Phase 1 clinical trial and provides an enrollment update. This trial is evaluating Deltacel™ (KB-GDT-01), the Company's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic or locally-advanced non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies. The fourth patient in Deltacel-01 demonstrated a partial response (defined as a 30% or greater decrease in the size of the tumor) at the eight-month follow-up visit and continued w
- SECSEC Form 10-K filed by Kiromic BioPharma Inc.10-K - Kiromic Biopharma, Inc. (0001792581) (Filer)
- SECAmendment: Kiromic BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K/A - Kiromic Biopharma, Inc. (0001792581) (Filer)
- SECKiromic BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Kiromic Biopharma, Inc. (0001792581) (Filer)
- PRKiromic BioPharma Reports Tumor Volume Decrease in Two Patients Enrolled in Deltacel-01Provides Enrollment Update for Phase 1 Study in Late-Stage Non-small Cell Lung Cancer Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") reports favorable efficacy results from the 12-month follow-up visit for the first patient and the two-month follow-up visit for the seventh patient enrolled in its Deltacel-01 Phase 1 clinical trial, and provides an enrollment update. This trial is evaluating Deltacel™ (KB-GDT-01), the Company's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic or locally-advanced non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies. At the 12-month post-treatment follow-up vi
- SECSEC Form S-1 filed by Kiromic BioPharma Inc.S-1 - Kiromic Biopharma, Inc. (0001792581) (Filer)
- PRKiromic BioPharma Reports 32% Decrease in Tumor Volume Eight Months Post-Treatment in Fourth Patient Enrolled in Deltacel-01Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") reports favorable ongoing efficacy results from the eight-month follow-up visit for the fourth patient enrolled in its Deltacel-01 Phase 1 clinical trial, and provides additional updates on the first and seventh patients. This trial is evaluating Deltacel™ (KB-GDT-01), the Company's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies. 8-Month Follow-Up for Patient #4: Partial Response with Tumor Reduction of 32% Preliminary results from the eight-month follow-up visit for the fourth patient enro
- SECKiromic BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Kiromic Biopharma, Inc. (0001792581) (Filer)
- PRKiromic BioPharma Announces Settlement of Previously Disclosed SEC InvestigationSEC declines to impose civil penalties in light of the Company's self-reporting, prompt remediation and cooperation Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") today announced that it has entered into a settlement agreement with the U.S. Securities and Exchange Commission (the "SEC"), resolving the previously disclosed SEC investigation arising from the non-disclosure by Kiromic's prior executive management of the clinical holds placed on the investigational new drug ("IND") applications the Company filed with the U.S. Food and Drug Administration (the "FDA") in May 2021. The IND applications pertained to ALEXIS-PRO-1 (Procel™) and ALEXIS-ISO-1 (Isocel™). In light of
- SECSEC Form 10-Q filed by Kiromic BioPharma Inc.10-Q - Kiromic Biopharma, Inc. (0001792581) (Filer)
- 13D/GAmendment: SEC Form SC 13G/A filed by Kiromic BioPharma Inc.SC 13G/A - Kiromic Biopharma, Inc. (0001792581) (Subject)
- SECKiromic BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Kiromic Biopharma, Inc. (0001792581) (Filer)
- PRKiromic BioPharma Reports Favorable Ongoing Clinical Results From Fourth and Sixth Patients Enrolled in Deltacel-01Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") reports favorable ongoing efficacy results from follow-up visits for Patient 4 and Patient 6 in its Deltacel-01 Phase 1 clinical trial. This trial is evaluating Deltacel™ (KB-GDT-01), the Company's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies. At the six-month follow-up visit, Patient 4 maintained stable disease with a 5.3% reduction in tumor size compared to the pre-treatment size. At the two-month follow-up visit, Patient 6 demonstrated stable disease with no new lesions detected and no si
- PRKiromic BioPharma Reports Favorable 10-Month Follow-Up Results for the First Patient Treated in its Deltacel-01 Clinical TrialKiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") reports good safety and favorable ongoing efficacy results from the 10-month follow-up visit of the first patient treated in its Deltacel-01 Phase 1 clinical trial. This trial is evaluating Deltacel™ (KB-GDT-01), the Company's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies. In this patient, the tumor size was reduced by approximately 27% compared with the pre-treatment size, and no new sites of disease were identified. As a result, the progression-free survival (PFS) has reached 10 months with
- SECKiromic BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Kiromic Biopharma, Inc. (0001792581) (Filer)
- PRKiromic BioPharma Activates the University of Arizona Cancer Center as the Fifth Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 TrialKiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") announces that the University of Arizona Cancer Center (UACC) has been activated as the fifth clinical trial site in the Deltacel-01 Phase 1 trial evaluating Deltacel™ (KB-GDT-01), Kiromic's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies. The UACC is one of the 57 NCI-Designated Comprehensive Cancer Centers in the U.S. Dr. Ricklie Ann Julian, Assistant Professor of Medicine at UACC, will serve as Principal Investigator at the site. "We are delighted to partner with UACC, expanding our Deltace
- PRKiromic BioPharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee's Unanimous RecommendationKiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") announced today that the Deltacel-01 Safety Monitoring Committee (SMC) has unanimously voted in favor of proceeding with the expansion phase of the Deltacel-01 clinical trial. This trial is evaluating Deltacel™ (KB-GDT-01), the Company's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies. This recommendation by the SMC follows a favorable review of safety data from the first two cohorts, including recent results from the 40-day follow-up visit of the sixth patient in Deltacel-01, which demonstrate
- INSIDERChief Executive Officer Bersani Pietro bought $7,407 worth of shares (3,488 units at $2.12), increasing direct ownership by 3% to 142,333 units (SEC Form 4)4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
- INSIDERChief Financial Officer Hungerford Brian bought $8,802 worth of shares (4,000 units at $2.20), increasing direct ownership by 7% to 64,933 units (SEC Form 4)4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
- INSIDERChief Financial Officer Hungerford Brian bought $3,500 worth of shares (2,000 units at $1.75), increasing direct ownership by 3% to 60,933 units (SEC Form 4)4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)
- PRKiromic BioPharma's Deltacel Receives FDA Fast Track DesignationKiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Deltacel™ (KB-GDT-01), the Company's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy. The designation was awarded for KB-GDT-01 in combination with low-dose radiation therapy for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have progressed on at least two lines of standard of care therapy including platinum-based chemotherapy, immune checkpoint inhibitors and targeted therapy to improve progression-free survival and overall survival. Deltacel is currently being evaluated in the Delta
- SECSEC Form 10-Q filed by Kiromic BioPharma Inc.10-Q - Kiromic Biopharma, Inc. (0001792581) (Filer)
KRBP FAQ
6 questionsWhat does Kiromic BioPharma Inc. do?
Kiromic BioPharma, Inc., a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1; and chimeric gamma delta PD1 T cell switch receptor therapy. It has license agreements with Mercer University; CGA 369 Intellectual Holdings, Inc.; and Longwood University, as well as research and...Where does KRBP stock trade?
Kiromic BioPharma Inc. (KRBP) is listed on NASDAQ.What sector and industry is KRBP in?
Kiromic BioPharma Inc. operates in the Health Care sector, Medicinal Chemicals and Botanical Products industry.When did Kiromic BioPharma Inc. go public?
Kiromic BioPharma Inc. (KRBP) completed its IPO in 2020.What companies are similar to KRBP?
Notable peers in the same industry include PM (Philip Morris International Inc), BTI (British American Tobacco Industries p.l.c.), MO (Altria Group Inc.), RGC (Regencell Bioscience Holdings Limited), RLX (RLX Technology Inc.). Compare KRBP side-by-side with any of them on Quantisnow.How can I track KRBP on Quantisnow?
Quantisnow aggregates Kiromic BioPharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KRBP to receive live email and push alerts on every new disclosure.